Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session: NSCLC metastatic

1259MO - Encorafenib plus binimetinib in patients (pts) with previously untreated BRAF V600E-mutant advanced non-small cell lung cancer (NSCLC): An open-label, multicenter phase II trial (IFCT-1904 ENCO-BRAF)

Date

14 Sep 2024

Session

Mini oral session: NSCLC metastatic

Topics

Targeted Therapy;  Genetic and Genomic Testing

Tumour Site

Non-Small Cell Lung Cancer

Presenters

David Planchard

Citation

Annals of Oncology (2024) 35 (suppl_2): S802-S877. 10.1016/annonc/annonc1602

Authors

D. Planchard1, J. Mazieres2, C. Mascaux3, F. Guisier4, P. Tomasini5, M. Wislez6, D. Moro-Sibilot7, S. Cousin8, A.B. Cortot9, S. Couraud10, V. Fallet11, C. Guguen12, A. Lagrange13, A. Madroszyk Flandin14, J. Otto15, M. Pérol16, B. Roch17, E. Amour18, F. Morin18, C. Ricordel19

Author affiliations

  • 1 Thoracic Cancer Group, Medical Oncology, Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 2 Thoracic Oncology, Centre Hospitalier Universitaire de Toulouse, 31059 - Toulouse/FR
  • 3 Pulmonology, Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, 67091 - Strasbourg/FR
  • 4 Pulmonology, CHU de Rouen Normandie, 76000 - Rouen/FR
  • 5 Multidisciplinary Oncology And Therapeutic Innovation, Assistance Publique Hôpitaux de Marseille, 13015 - Marseille/FR
  • 6 Thoracic Oncology, Hôpital Cochin (Hôpitaux Universitaires Paris Centre), 75679 - Paris/FR
  • 7 Thoracic Oncology, CHU Grenoble Alpes, 38043 - Grenoble/FR
  • 8 Medical Oncology, Institut Bergonie, 33076 - Bordeaux/FR
  • 9 Thoracic Oncology, Institut Cœur Poumon, 59037 - Lille/FR
  • 10 Pulmonology, Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite/FR
  • 11 Pulmonology And Thoracic Oncology, Tenon Hospital, Assistance Publique Hôpitaux de Paris and GRC 4, Theranoscan, Sorbonne Université, 75020 - Paris/FR
  • 12 Pulmonology, Centre Hospitalier Général du Mans, 72037 - Le Mans/FR
  • 13 Oncology, Centre Georges-François Leclerc, 21000 - Dijon/FR
  • 14 Medical Oncology, IPC - Institut Paoli-Calmettes, 13273 - Marseille, Cedex/FR
  • 15 Oncology, Centre Antoine Lacassagne, 06189 - Nice/FR
  • 16 Medical Oncology, Centre Léon Bérard, 69373 - Lyon/FR
  • 17 Thoracic Oncology, Arnaud de Villeneuve University Hospital, 34295 - Montpellier/FR
  • 18 Clinical Research Unit, French Cooperative Thoracic Intergroup (IFCT), 75009 - Paris/FR
  • 19 Pulmonology, Hopital Pontchaillou, CHU Rennes, INSERM, OSS, UMR_S 1242, Univ Rennes 1, 35033 - Rennes/FR

Resources

This content is available to ESMO members and event participants.

Abstract 1259MO

Background

Activating BRAF-V600 mutations are oncogenic drivers in NSCLC. Current ESMO guidelines recommend dabrafenib plus trametinib as preferred first-line treatment options or as subsequent treatment for BRAFV600E-mutant advanced NSCLC. The combination of BRAF inhibitor encorafenib plus MEK inhibitor binimetinib has demonstrated clinical efficacy in patients with BRAFV600E-mutant NSCLC and melanoma.

Methods

In this ongoing, open-label, single-arm phase 2 study (IFCT-1904), BRAFV600E-mutant NSCLC pts received encorafenib 450mg once daily plus binimetinib 45mg twice daily. Cohort A enrolled previously untreated pts (presented in this abstract) and cohort B pretreated pts. The primary endpoint was investigator-assessed overall response rate (ORR). Secondary endpoints included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety.

Results

Cohort A enrolled 64 pts from 24 centres in France between Mar 2021 and Sept 2023. Median age was 70.7 years; 47% were males; 17.2% had baseline brain metastases and 35.9% were never-smokers. Median follow-up in the study was 18 months. Median duration of treatment was 8.8 months with encorafenib and 8.9 months with binimetinib. Investigator-assessed ORR was 66.7% (95% IC: 55.0% - 78.3%). Median DOR was 13 months (95% IC: 9.1-NR) and DCR was 85.7% (95% IC: 77.1% - 94.4%). Median PFS was 11.1 months (95% IC: 7.1-16.7) and median OS was not reached (95% IC: 20.7-NR). The most frequent treatment-related adverse events (TRAEs) were fatigue (42.2%), nausea (32.8%) and diarrhea (31.3%). The percentage of pts with at least one dose reduction was 34.4% for encorafenib and 32.8% for binimetinib (of which 90% for AE). Permanent discontinuation of encorafenib plus binimetinib due to TRAE occurred in 6/38 (15.8%) pts. Grade 3 TRAE retinal detachment was observed in 3 pts (4.7%).

Conclusions

In this phase 2 trial with treatment-naïve BRAFV600E-mutant advanced NSCLC, encorafenib plus binimetinib demonstrated robust clinical activity. The safety profile was manageable and consistent with previous studies in lung cancer and melanoma.

Clinical trial identification

EudraCT 2019-004621-24, NCT04526782.

Editorial acknowledgement

Legal entity responsible for the study

IFCT.

Funding

Pierre Fabre France + IFCT.

Disclosure

D. Planchard: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Samsung, Celgene, AbbVie, Daiichi Sankyo, Janssen, Seagen, Gilead, Pierre Fabre; Financial Interests, Personal, Invited Speaker: AstraZeneca, Novartis, Pfizer, priME Oncology, Peer CME, Samsung, AbbVie, Janssen; Non-Financial Interests, Principal Investigator, Institutional financial interests: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Daiichi Sankyo, Sanofi-Aventis, Pierre Fabre; Non-Financial Interests, Principal Investigator: AbbVie, Sanofi, Janssen. J. Mazieres: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Pierre Fabre, Takeda, BMS, MSD, Pfizer, Jiangsu Hengruii, Blueprint, Daiichi Sankyo, Novartis, Amgen; Financial Interests, Institutional, Other: Roche, AstraZeneca, Pierre Fabre, BMS, Illumina. C. Mascaux: Financial Interests, Personal, Invited Speaker: AstraZeneca, Roche, Bristol Myers Squibb, Pfizer, MSD, Amgen; Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, Roche, Bristol Myers Squibb, Pfizer, Kephren, Janssens, Takeda, Sanofi, Novartis. F. Guisier: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, MSD, Roche, Sanofi, Janssen, Pfizer, Takeda; Financial Interests, Institutional, Research Grant: Pfizer, Roche, Takeda. P. Tomasini: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, BMS, Lilly, Janssen, Amgen, Takeda; Financial Interests, Institutional, Local PI: Roche, AstraZeneca, Amgen, Lilly, Takeda; Financial Interests, Institutional, Coordinating PI: Janssen. M. Wislez: Financial Interests, Personal, Speaker’s Bureau: Amgen, Bristol Myers Squibb, F. Hoffman La Roche, Janssen, MSD Oncology, AstraZeneca, Sanofi; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bristol Myers Squibb, Janssen, MSD Oncology, Sanofi; Non-Financial Interests, Personal, Advisory Board: F. Hoffman La Roche; Financial Interests, Personal, Other: F. Hoffman La Roche, Janssen; Non-Financial Interests, Institutional, Principal Investigator: MSD Oncology, Amgen, AstraZeneca, Bristol Myers Squibb, F. Hoffman La Roche, Janssen, Novartis, Merus, BeiGene, Dizal, AbbVie, Boehringer Ingelheim, Lilly, Verastem. D. Moro-Sibilot: Financial Interests, Personal, Advisory Board: Novartis, Roche, Pierre Fabre. S. Cousin: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, Lilly, Roche; Non-Financial Interests, Principal Investigator: AstraZeneca, Daichi, Gilead, Takeda, Sanofi, MSD, GSK, BMS. A.B. Cortot: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, AstraZeneca, MSD, Pfizer, Novartis, Takeda, Roche; Financial Interests, Personal, Advisory Board: Novartis, Roche, Pfizer, Janssen, Exeliom, Amgen; Financial Interests, Institutional, Research Grant: Merck, Roche, AbbVie, Exeliom; Financial Interests, Institutional, Coordinating PI: AstraZeneca; Financial Interests, Institutional, Local PI: Janssen, Roche, Sparta, Amgen, Mirati, AbbVie; Non-Financial Interests, Member of Board of Directors: French Thoracic Intergroup. S. Couraud: Financial Interests, Institutional, Funding: Adene, BD Bioscience, Cellgene, Chugai, Janssen, Lilly, Takeda, Transdiag, Volition; Financial Interests, Personal and Institutional, Funding: Amgen, AstraZeneca, BMS, Boehringer Ingelheim, MSD, Novartis, Pfizer, Roche, Sanofi; Financial Interests, Personal, Funding: Health Event, Maat Pharma, Pierre Fabre; Non-Financial Interests, Leadership Role: National guidelines in thoracic oncology (ARISTOT); Non-Financial Interests, Member of Board of Directors: Société de Pneumologie de Langue Française, Adene. V. Fallet: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, F. Hoffman La Roche, Jansen, MSD Oncology, Novartis, Pfizer, Sanofi, Takeda. A. Madroszyk Flandin: Financial Interests, Personal, Advisory Board, board 24/05/23: Janssen; Financial Interests, Personal, Advisory Board, 10/2021: AstraZeneca. M. Pérol: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, MSD, BMS, Lilly, Novartis, Takeda, Gritstone, Sanofi, Pfizer, Amgen, Janssen, GSK, Eisai, Ipsen, AstraZeneca, AbbVie, AnHeart Therapeutics, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, MSD, BMS, Boehringer Ingelheim, Takeda, Illumina, Pfizer, Medscape; Financial Interests, Personal, Advisory Board, Advisory board: Novocure; Financial Interests, Institutional, Research Grant: AstraZeneca, ROCHE, Takeda, Boehringer Ingelheim; Financial Interests, Personal, Steering Committee Member: Roche, Sophiagenetics, PharmaMar, AnHeart Therapeutics; Financial Interests, Personal, Other, DMSB: Roche; Financial Interests, Institutional, Local PI: AstraZeneca, Amgen, Roche, AbbVie, Apollomics, AnHeart Therapeutics, Innate Pharma, Boehringer Ingelheim, Arrivent Biopharma, Daiichi Sankyo, Bayer; Financial Interests, Steering Committee Member: Lilly. C. Ricordel: Financial Interests, Personal, Advisory Board: Roche, Takeda, MSD, BMS, Janssen, Sanofi, AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.